Cellectar Biosciences (CLRB) Non-Current Assets (2010 - 2026)
Cellectar Biosciences (CLRB) posted Non-Current Assets of $939856.0 for Q4 2025, down 6.56% sequentially from $1.0 million in Q3 2025, and down 23.2% YoY from $1.2 million in Q4 2024.
Cellectar Biosciences (CLRB) Non-Current Assets (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Non-Current Assets for 16 years, with the latest figure at $939856.0 in Q4 2025.
- Quarterly Non-Current Assets fell 23.2% year-over-year to $939856.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (down 25.98% YoY) and the FY2025 annual result came in at $939856.0, down 23.2% from the prior year.
- Non-Current Assets slipped to $939856.0 in Q4 2025 per CLRB's latest filing, from $1.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.6 million in Q4 2023 and troughed at $558255.0 in Q3 2022.
- A 5-year average of $1.0 million and a median of $998956.0 in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2023: Non-Current Assets tumbled 37.29% in 2021, then surged 158.1% in 2023.
- Over 5 years, Non-Current Assets stood at $630349.0 in 2021, then soared by 68.19% to $1.1 million in 2022, then soared by 53.03% to $1.6 million in 2023, then decreased by 24.57% to $1.2 million in 2024, then declined by 23.2% to $939856.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $939856.0, $1.0 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 18.06 Bn |
| 10 | Cellectar Biosciences | 6.52 Mn | 6.52 Mn | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Dec 31, 2025 | 939,856.00 |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 899,514.00 |
| Mar 31, 2023 | 992,020.00 |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 558,255.00 |
| Jun 30, 2022 | 607,163.00 |
| Mar 31, 2022 | 595,644.00 |
| Dec 31, 2021 | 630,349.00 |
| Sep 30, 2021 | 560,460.00 |
| Jun 30, 2021 | 612,975.00 |